Effectiveness of Vandetanib for unresectable medullary thyroid cancer

DOI Web Site 11 References Open Access
  • Yamada Hiroyuki
    Department of Otorhinolaryngology Head and Neck, Ise Red Cross Hospital
  • Fuke Tomohito
    Department of Otorhinolaryngology Head and Neck, Ise Red Cross Hospital
  • Fukukita Kohei
    Department of Otorhinolaryngology Head and Neck, Ise Red Cross Hospital
  • Kaneko Mamika
    Department of Otorhinolaryngology Head and Neck, Ise Red Cross Hospital
  • Sawa Masahiro
    Department of Otorhinolaryngology Head and Neck, Ise Red Cross Hospital
  • Ueda Koki
    Department of Otorhinolaryngology Head and Neck, Ise Red Cross Hospital
  • Kobayashi Daisuke
    Department of Otorhinolaryngology Head and Neck, Ise Red Cross Hospital

Bibliographic Information

Other Title
  • 根治手術困難な甲状腺髄様癌に対するバンデタニブの使用経験

Search this article

Description

Surgical therapy is the main strategy for medullary thyroid cancer, but there is no effective therapy for resectable advanced cases. Vandetanib is a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling. We experienced a case medicated by Vandetanib for medullary thyroid cancer. A 55-year-old female was diagnosed with medullary thyroid cancer by aspiration cytology of a thyroid tumor and needle biopsy histology. Since FDG-PET showed multiple bone metastases, she was treated with Vandetanib. Serum calcitonin and carcinoembryonic antigen decreased after withdrawal of the medication, and US showed decreased size of the thyroid tumor and cervical lymph nodes similarly. Since PET-CT showed decreased accumulation into these nodules, she was judged to have responded to the treatment. Though Vandetanib is a first-line TKI for unresectable medullary thyroid cancer, the purpose of this therapy is to control progression of the cancer.

Journal

  • Toukeibu Gan

    Toukeibu Gan 45 (1), 71-75, 2019

    Japan Society for Head and Neck Cancer

References(11)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top